A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients

Clinical Lung Cancer

Volumn 18, Issue 5, 2017, Pages 572-582.e1

  Takada, Kazuki ^a   Toyokawa, Gouji ^a   Okamoto, Tatsuro ^a   Shimokawa, Mototsugu ^b   Kozuma, Yuka ^a   Matsubara, Taichi ^a   Haratake, Naoki ^a   Akamine, Takaki ^a   Takamori, Shinkichi ^a   Katsura, Masakazu ^a   Shoji, Fumihiro ^a   Oda, Yoshinao ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Immunohistochemistry; Immunotherapy; Lung cancer; Programmed cell death ligand 1; Programmed cell death 1

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ATEZOLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; UFT; ANTIBODY; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; OVERALL SURVIVAL; PLEURA METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; TRANSLATIONAL RESEARCH; BLOOD VESSEL; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; SEX FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; BLOOD VESSELS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING; SURVIVAL RATE;

EID: 85015367545     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2017.02.004     Document Type: Article

References (38)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J Clin 62 (2012), 10–29.
2. Morgensztern, D., Campo, M.J., Dahlberg, S.E., et al. Molecularly targeted therapies in non–small-cell lung cancer annual update 2014. J Thorac Oncol 10 (2015), S1–S63.
3. Oxnard, G.R., Binder, A., Janne, P.A., New targetable oncogenes in non–small-cell lung cancer. J Clin Oncol 31 (2013), 1097–1104.
4. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
5. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
6. Gatalica, Z., Snyder, C., Maney, T., et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol 23 (2014), 2965–2970.
7. Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
8. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
9. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
10. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
11. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
12. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
13. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
14. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non–small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
15. Sheng, J., Fang, W., Yu, J., et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non–small-cell lung cancer. Sci Rep, 6, 2016, 20090.
16. Kohno, M., Okamoto, T., Suda, K., et al. Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. Clin Cancer Res 20 (2014), 3613–3622.
17. Takada, K., Toyokawa, G., Okamoto, T., et al. An immunohistochemical analysis of PD-L1 protein expression in surgically resected small cell lung cancer using different antibodies and criteria. Anticancer Res 36 (2016), 3409–3412.
18. Takada, K., Okamoto, T., Shoji, F., et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol 11 (2016), 1879–1890.
19. McLaughlin, J., Han, G., Schalper, K.A., et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol 2 (2016), 46–54.
20. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
21. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr, Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
22. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non–small-cell lung cancer. Science 348 (2015), 124–128.
23. Champiat, S., Ferte, C., Lebel-Binay, S., Eggermont, A., Soria, J.C., Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology, 3, 2014, e27817.
24. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
25. Carbognin, L., Pilotto, S., Milella, M., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10, 2015, e0130142.
26. Mu, C.Y., Huang, J.A., Chen, Y., Chen, C., Zhang, X.G., High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28 (2011), 682–688.
27. Azuma, K., Ota, K., Kawahara, A., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non–small-cell lung cancer. Ann Oncol 25 (2014), 1935–1940.
28. Chen, Y.B., Mu, C.Y., Huang, J.A., Clinical significance of programmed death-1 ligand-1 expression in patients with non–small-cell lung cancer: a 5-year-follow-up study. Tumori 98 (2012), 751–755.
29. Velcheti, V., Schalper, K.A., Carvajal, D.E., et al. Programmed death ligand-1 expression in non–small-cell lung cancer. Lab Invest 94 (2014), 107–116.
30. Cooper, W.A., Tran, T., Vilain, R.E., et al. PD-L1 expression is a favorable prognostic factor in early stage non–small-cell carcinoma. Lung Cancer 89 (2015), 181–188.
31. Schmidt, L.H., Kummel, A., Gorlich, D., et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One, 10, 2015, e0136023.
32. Kim, M.Y., Koh, J., Kim, S., Go, H., Jeon, Y.K., Chung, D.H., Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 88 (2015), 24–33.
33. Zhang, Y., Wang, L., Li, Y., et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 7 (2014), 567–573.
34. Yang, C.Y., Lin, M.W., Chang, Y.L., Wu, C.T., Yang, P.C., Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50 (2014), 1361–1369.
35. D'Incecco, A., Andreozzi, M., Ludovini, V., et al. PD-1 and PD-L1 expression in molecularly selected non–small-cell lung cancer patients. Br J Cancer 112 (2015), 95–102.
36. Boland, J.M., Kwon, E.D., Harrington, S.M., et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 14 (2013), 157–163.
37. Shimoji, M., Shimizu, S., Sato, K., et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 98 (2016), 69–75.
38. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.